252 related articles for article (PubMed ID: 10520851)
21. Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation.
Papadia C; Sherwood RA; Kalantzis C; Wallis K; Volta U; Fiorini E; Forbes A
Am J Gastroenterol; 2007 Jul; 102(7):1474-82. PubMed ID: 17459021
[TBL] [Abstract][Full Text] [Related]
22. [Intestinal permeability in relatives of patients with Crohn's disease].
Kohout P; Koref P
Vnitr Lek; 2001 Jun; 47(6):371-4. PubMed ID: 11494882
[TBL] [Abstract][Full Text] [Related]
23. Comparison between lactulose-mannitol test and 51Cr-labelled ethylene diamine tetra-acetate test in inflammatory bowel diseases.
Andre C; Descos L; Minaire Y
Hepatogastroenterology; 1990 Dec; 37 Suppl 2():113-7. PubMed ID: 2128072
[TBL] [Abstract][Full Text] [Related]
24. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
25. Correlation between levels of C-reactive protein and clinical activity in Crohn's disease.
Karoui S; Ouerdiane S; Serghini M; Jomni T; Kallel L; Fekih M; Boubaker J; Filali A
Dig Liver Dis; 2007 Nov; 39(11):1006-10. PubMed ID: 17889628
[TBL] [Abstract][Full Text] [Related]
26. Oral butyrate for mildly to moderately active Crohn's disease.
Di Sabatino A; Morera R; Ciccocioppo R; Cazzola P; Gotti S; Tinozzi FP; Tinozzi S; Corazza GR
Aliment Pharmacol Ther; 2005 Nov; 22(9):789-94. PubMed ID: 16225487
[TBL] [Abstract][Full Text] [Related]
27. [Predictive factors of intestinal stenosis in Crohn's disease].
Elloumi H; Ben Abdelaziz A; Sfar S; Arfaoui D; Ben Slama A; Ghouma M; Ajmi S
Tunis Med; 2006 Nov; 84(11):711-3. PubMed ID: 17294896
[TBL] [Abstract][Full Text] [Related]
28. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy.
Allez M; Lemann M; Bonnet J; Cattan P; Jian R; Modigliani R
Am J Gastroenterol; 2002 Apr; 97(4):947-53. PubMed ID: 12003431
[TBL] [Abstract][Full Text] [Related]
29. Intestinal permeability is increased in a proportion of spouses of patients with Crohn's disease.
Breslin NP; Nash C; Hilsden RJ; Hershfield NB; Price LM; Meddings JB; Sutherland LR
Am J Gastroenterol; 2001 Oct; 96(10):2934-8. PubMed ID: 11693329
[TBL] [Abstract][Full Text] [Related]
30. "Crohn's disease activity index" is inaccurate to detect the post-operative recurrence in Crohn's disease. A GISC study. Gruppo Italiano per lo Studio del Colon e del Retto.
Viscido A; Corrao G; Taddei G; Caprilli R
Ital J Gastroenterol Hepatol; 1999 May; 31(4):274-9. PubMed ID: 10425569
[TBL] [Abstract][Full Text] [Related]
31. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study).
Henriksen M; Jahnsen J; Lygren I; Aadland E; Schulz T; Vatn MH; Moum B;
Scand J Gastroenterol; 2007 May; 42(5):602-10. PubMed ID: 17454881
[TBL] [Abstract][Full Text] [Related]
32. Pediatric Crohn's disease: risk factors for postoperative recurrence.
Baldassano RN; Han PD; Jeshion WC; Berlin JA; Piccoli DA; Lautenbach E; Mick R; Lichtenstein GR
Am J Gastroenterol; 2001 Jul; 96(7):2169-76. PubMed ID: 11467649
[TBL] [Abstract][Full Text] [Related]
33. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
34. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
[TBL] [Abstract][Full Text] [Related]
35. Increased urinary F2-isoprostanes in patients with Crohn's disease.
Cracowski JL; Bonaz B; Bessard G; Bessard J; Anglade C; Fournet J
Am J Gastroenterol; 2002 Jan; 97(1):99-103. PubMed ID: 11808977
[TBL] [Abstract][Full Text] [Related]
36. [Measurement of selective intestinal permeability using a new, simple sugar absorption test].
van Elburg RM; Kokke FT; Uil JJ; Mulder CJ; de Monchy JG; Heymans HS
Ned Tijdschr Geneeskd; 1993 Oct; 137(41):2091-5. PubMed ID: 8413731
[TBL] [Abstract][Full Text] [Related]
37. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance.
Atkinson AB; Kennedy A; Wiggam MI; McCance DR; Sheridan B
Clin Endocrinol (Oxf); 2005 Nov; 63(5):549-59. PubMed ID: 16268808
[TBL] [Abstract][Full Text] [Related]
38. Factors affecting recurrence in patients with Crohn's disease under nutritional therapy.
Esaki M; Matsumoto T; Nakamura S; Yada S; Fujisawa K; Jo Y; Iida M
Dis Colon Rectum; 2006 Oct; 49(10 Suppl):S68-74. PubMed ID: 17106818
[TBL] [Abstract][Full Text] [Related]
39. Increased intestinal permeability in patients with inflammatory bowel disease.
Welcker K; Martin A; Kölle P; Siebeck M; Gross M
Eur J Med Res; 2004 Oct; 9(10):456-60. PubMed ID: 15546811
[TBL] [Abstract][Full Text] [Related]
40. CD19+ in intestinal mucosa predict the response to infliximab in Crohn's disease.
Ferkolj I; Ihan A; Markovic S
Hepatogastroenterology; 2005; 52(64):1128-33. PubMed ID: 16001645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
